Safety & Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Launched by RETINA IMPLANT AG · Dec 19, 2011
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hereditary retinal degeneration of the outer retinal layers i.e. photoreceptor rods \& cones.
- • Pseudophakia
- • Angiography shows retinal vessels adequately perfused, despite pathological RP condition.
- • Age between 18 and 78 years.
- • Blindness (at least monocular) i.e. visual functions not appropriate for localization of objects, self sustained navigation and orientation (impaired light localization or worse).
- • Ability to read normal print in earlier life, optically corrected without magnifying glass.
- • Willing and able to give written informed consent in accordance to EN ISO 14155 (section 6.7) and local legislation prior to participation in the study. Able to perform the study during the full time period of one year
- Exclusion Criteria:
- • Period of appropriate visual functions \< 12 years / lifetime.
- • Optical Coherence Tomography (OCT) shows significant retina edema \&/or scar tissue within target region for implant.
- • Retina detected as too thin to expect required rest-functionality of inner retina as shown via Optical Coherence Tomography (OCT).
- • Lack of inner-retinal function, as determined by Electrically Evoked Phosphenes (EEP).
- • Heavy clumped pigmentation at posterior pole
- • Any other ophthalmologic disease with relevant effect upon visual function (e.g. glaucoma, optic neuropathies, trauma, diabetic retinopathy, retinal detachment).
- • Amblyopia reported earlier in life on eye to be implanted
- • Systemic diseases that might imply considerable risks with regard to the surgical interventions and anaesthesia (e.g. cardiovascular/ pulmonary diseases, severe metabolic diseases).
- • Neurological and/or psychiatric diseases (e.g. M. Parkinson, epilepsy, depression).
- • Hyperthyroidism or hypersensitivity to iodine
- • Women who are pregnant or nursing, or women of childbearing potential who are not willing to use a medically acceptable means of birth control for the duration of the study, or women unwilling to perform a pregnancy test before entering the study.
- • Participation in another interventional clinical trial within the past 30 days.
About Retina Implant Ag
Retina Implant AG is a pioneering medical technology company focused on developing innovative solutions for patients with vision loss due to retinal diseases. Based in Germany, the company specializes in advanced implantable devices designed to restore vision by directly stimulating the retina. With a commitment to enhancing patient quality of life, Retina Implant AG conducts rigorous clinical trials to validate the safety and efficacy of its products. The company collaborates with leading research institutions and healthcare professionals to advance retinal therapies and contribute to the future of ophthalmic medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Cyberport, Hong Kong
Patients applied
Trial Officials
David Wong, Prof., MD
Principal Investigator
Chair Professor in Ophthalmology Eye Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials